到底为啥呢_老虎社区_美港股上老虎

到底为啥呢

Stock Track | Iovance Stock Plunges Despite Strong Q3 Results and Positive Updates

Iovance Biotherapeutics, Inc. saw its stock price plunge by 9.61% in after-hours trading on November 7, 2024, despite reporting strong financial results and positive corporate updates for the third quarter and first nine months of 2024.The biotechnology company announced total revenue of $58.6 million in the third quarter, primarily driven by $42.1 million in sales of its newly launched cancer therapy Amtagvi and $16.5 million in sales of Proleukin, which is used in the Amtagvi treatment regim

Stock Track | Iovance Stock Plunges Despite Strong Q3 Results and Positive Updates

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":368697576743328,"tweetId":"368697576743328","gmtCreate":1731055539015,"gmtModify":1731055540523,"author":{"id":3537417120281286,"idStr":"3537417120281286","authorId":3537417120281286,"authorIdStr":"3537417120281286","name":"润土34000_5000","avatar":"https://static.tigerbbs.com/ed03e24159cdfb1a1cc9e0eb75d70106","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>到底为啥呢</p></body></html>","htmlText":"<html><head></head><body><p>到底为啥呢</p></body></html>","text":"到底为啥呢","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/368697576743328","repostId":1156163553,"repostType":2,"repost":{"id":"1156163553","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1731049863,"share":"https://www.laohu8.com/m/news/1156163553?lang=&edition=full","pubTime":"2024-11-08 15:11","market":"hk","language":"en","title":"Stock Track | Iovance Stock Plunges Despite Strong Q3 Results and Positive Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1156163553","media":"Stock Track","summary":"Iovance Biotherapeutics, Inc.  saw its stock price plunge by 9.61% in after-hours trading on November 7, 2024, despite reporting strong financial results and positive corporate updates for the third quarter and first nine months of 2024.The biotechnology company announced total revenue of $58.6 million in the third quarter, primarily driven by $42.1 million in sales of its newly launched cancer therapy Amtagvi  and $16.5 million in sales of Proleukin, which is used in the Amtagvi treatment regim","content":"<p>Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) saw its stock price plunge by 9.61% in after-hours trading on November 7, 2024, despite reporting strong financial results and positive corporate updates for the third quarter and first nine months of 2024.</p>\n\n<p>The biotechnology company announced total revenue of $58.6 million in the third quarter, primarily driven by $42.1 million in sales of its newly launched cancer therapy Amtagvi (lifileucel) and $16.5 million in sales of Proleukin, which is used in the Amtagvi treatment regimen. This represented a significant increase from the prior year, driven by the successful commercial launch of Amtagvi in the U.S. in February 2024.</p>\n\n<p>Iovance reaffirmed its guidance for total product revenue in the range of $160 to $165 million for the full year 2024, reflecting three quarters of Amtagvi sales. The company also maintained its guidance for total product revenue in the range of $450 to $475 million for the full year 2025, the first full calendar year of Amtagvi sales.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Stock Plunges Despite Strong Q3 Results and Positive Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Stock Plunges Despite Strong Q3 Results and Positive Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-08 15:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) saw its stock price plunge by 9.61% in after-hours trading on November 7, 2024, despite reporting strong financial results and positive corporate updates for the third quarter and first nine months of 2024.</p>\n\n<p>The biotechnology company announced total revenue of $58.6 million in the third quarter, primarily driven by $42.1 million in sales of its newly launched cancer therapy Amtagvi (lifileucel) and $16.5 million in sales of Proleukin, which is used in the Amtagvi treatment regimen. This represented a significant increase from the prior year, driven by the successful commercial launch of Amtagvi in the U.S. in February 2024.</p>\n\n<p>Iovance reaffirmed its guidance for total product revenue in the range of $160 to $165 million for the full year 2024, reflecting three quarters of Amtagvi sales. The company also maintained its guidance for total product revenue in the range of $450 to $475 million for the full year 2025, the first full calendar year of Amtagvi sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156163553","content_text":"Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) saw its stock price plunge by 9.61% in after-hours trading on November 7, 2024, despite reporting strong financial results and positive corporate updates for the third quarter and first nine months of 2024.\nThe biotechnology company announced total revenue of $58.6 million in the third quarter, primarily driven by $42.1 million in sales of its newly launched cancer therapy Amtagvi (lifileucel) and $16.5 million in sales of Proleukin, which is used in the Amtagvi treatment regimen. This represented a significant increase from the prior year, driven by the successful commercial launch of Amtagvi in the U.S. in February 2024.\nIovance reaffirmed its guidance for total product revenue in the range of $160 to $165 million for the full year 2024, reflecting three quarters of Amtagvi sales. The company also maintained its guidance for total product revenue in the range of $450 to $475 million for the full year 2025, the first full calendar year of Amtagvi sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":126,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}